Immunovant Q3 net loss smaller than expected

Reuters02-06

Immunovant Q3 net loss smaller than expected

Overview

Clinical-stage immunology firm's Q3 net loss beat analyst expectations
Company completed $550 mln financing, extending cash runway for IMVT-1402 launch
R&D expenses rose due to IMVT-1402 clinical trial activities

Outlook

Immunovant expects topline data for IMVT-1402 trials in 2026 and 2027
Company anticipates batoclimab Phase 3 data in first half of 2026
Immunovant extends cash runway to support IMVT-1402 launch in Graves’ disease

Result Drivers

R&D EXPENSES - Increase in R&D expenses primarily due to IMVT-1402 clinical trials and contract manufacturing costs
FINANCING - $550 mln financing completed, extending cash runway for IMVT-1402 launch
CLINICAL TRIAL PROGRESS - IMVT-1402 trials across multiple indications remain on track

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income	Beat	-$110.64 mln	-$125.06 mln (12 Analysts)
Q3 Basic EPS		-$0.61
Q3 Operating Expenses		$114.36 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Immunovant Inc is $44.00, about 82.9% above its February 5 closing price of $24.06

Press Release: ID:nGNX39KTkZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609598617?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609598617","market":"nz","top_or_hot":-1,"title":"Immunovant Q3 net loss smaller than expected","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Immunovant Q3 net loss smaller than expected</title></head><body><p><span>Overview</span></p><ul><li><p>Clinical-stage immunology firm's Q3 net loss beat analyst expectations</p></li><li><p>Company completed $550 mln financing, extending cash runway for IMVT-1402 launch</p></li><li><p>R&amp;D expenses rose due to IMVT-1402 clinical trial activities</p></li></ul><p><span>Outlook</span></p><ul><li><p>Immunovant expects topline data for IMVT-1402 trials in 2026 and 2027</p></li><li><p>Company anticipates batoclimab Phase 3 data in first half of 2026</p></li><li><p>Immunovant extends cash runway to support IMVT-1402 launch in Graves’ disease</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increase in R&amp;D expenses primarily due to IMVT-1402 clinical trials and contract manufacturing costs</p></li><li><p>FINANCING - $550 mln financing completed, extending cash runway for IMVT-1402 launch</p></li><li><p>CLINICAL TRIAL PROGRESS - IMVT-1402 trials across multiple indications remain on track</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$110.64 mln</p></td><td><p>-$125.06 mln (12 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.61</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$114.36 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 13 \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Immunovant Inc is $44.00, about 82.9% above its February 5 closing price of $24.06</p></li></ul><p>Press Release: <span>ID:nGNX39KTkZ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunovant Q3 net loss smaller than expected</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunovant Q3 net loss smaller than expected\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-06 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Immunovant Q3 net loss smaller than expected</title></head><body><p><span>Overview</span></p><ul><li><p>Clinical-stage immunology firm's Q3 net loss beat analyst expectations</p></li><li><p>Company completed $550 mln financing, extending cash runway for IMVT-1402 launch</p></li><li><p>R&amp;D expenses rose due to IMVT-1402 clinical trial activities</p></li></ul><p><span>Outlook</span></p><ul><li><p>Immunovant expects topline data for IMVT-1402 trials in 2026 and 2027</p></li><li><p>Company anticipates batoclimab Phase 3 data in first half of 2026</p></li><li><p>Immunovant extends cash runway to support IMVT-1402 launch in Graves’ disease</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increase in R&amp;D expenses primarily due to IMVT-1402 clinical trials and contract manufacturing costs</p></li><li><p>FINANCING - $550 mln financing completed, extending cash runway for IMVT-1402 launch</p></li><li><p>CLINICAL TRIAL PROGRESS - IMVT-1402 trials across multiple indications remain on track</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$110.64 mln</p></td><td><p>-$125.06 mln (12 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.61</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$114.36 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 13 \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Immunovant Inc is $44.00, about 82.9% above its February 5 closing price of $24.06</p></li></ul><p>Press Release: <span>ID:nGNX39KTkZ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMVT","symbol_name":"Immunovant, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL1N3Z20K1:1","article_id":"2609598617","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609598617","pubTimestamp":1770379698,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immunovant Q3 net loss smaller than expectedOverviewClinical-stage immunology firm's Q3 net loss beat analyst expectationsCompany completed $550 mln financing, extending cash runway for IMVT-1402 laun","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMVT":"Immunovant, Inc.","BK4588":"碎股","ROIV":"Roivant Sciences Ltd.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Immunovant第三季度净亏损小于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMVT":0.9,"ROIV":0.9},"content_text":"Immunovant Q3 net loss smaller than expectedOverviewClinical-stage immunology firm's Q3 net loss beat analyst expectationsCompany completed $550 mln financing, extending cash runway for IMVT-1402 launchR&D expenses rose due to IMVT-1402 clinical trial activitiesOutlookImmunovant expects topline data for IMVT-1402 trials in 2026 and 2027Company anticipates batoclimab Phase 3 data in first half of 2026Immunovant extends cash runway to support IMVT-1402 launch in Graves’ diseaseResult DriversR&D EXPENSES - Increase in R&D expenses primarily due to IMVT-1402 clinical trials and contract manufacturing costsFINANCING - $550 mln financing completed, extending cash runway for IMVT-1402 launchCLINICAL TRIAL PROGRESS - IMVT-1402 trials across multiple indications remain on trackKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net IncomeBeat-$110.64 mln-$125.06 mln (12 Analysts)Q3 Basic EPS-$0.61Q3 Operating Expenses$114.36 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 13 \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Immunovant Inc is $44.00, about 82.9% above its February 5 closing price of $24.06Press Release: ID:nGNX39KTkZFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609598617","isCrawlerRequest":true}